MX2019012012A - Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3. - Google Patents
Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3.Info
- Publication number
- MX2019012012A MX2019012012A MX2019012012A MX2019012012A MX2019012012A MX 2019012012 A MX2019012012 A MX 2019012012A MX 2019012012 A MX2019012012 A MX 2019012012A MX 2019012012 A MX2019012012 A MX 2019012012A MX 2019012012 A MX2019012012 A MX 2019012012A
- Authority
- MX
- Mexico
- Prior art keywords
- associated diseases
- methods
- compositions
- ccr3 inhibitors
- retinal
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000002207 retinal effect Effects 0.000 abstract 2
- 230000004304 visual acuity Effects 0.000 abstract 2
- 230000000007 visual effect Effects 0.000 abstract 2
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 201000005667 central retinal vein occlusion Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Se proporcionan métodos para mejorar los criterios de valoración visuales relacionados con las enfermedades asociadas a la retina con agentes moduladores de CCR3. Un ejemplo de tal criterio de valoración es la agudeza visual. Las enfermedades asociadas a la retina al respecto de las cuales se puede mejorar la agudeza visual y otros criterios de valoración visuales incluyen retinopatía del prematuro, degeneración macular relacionada con la edad, oclusión de la vena central de la retina y retinopatía diabética.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482134P | 2017-04-05 | 2017-04-05 | |
| PCT/US2018/026091 WO2018187473A1 (en) | 2017-04-05 | 2018-04-04 | Methods and compositions for treating retina-associated disease using ccr3-inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019012012A true MX2019012012A (es) | 2019-12-11 |
| MX394915B MX394915B (es) | 2025-03-24 |
Family
ID=62067800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019012012A MX394915B (es) | 2017-04-05 | 2018-04-04 | Metodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11590118B2 (es) |
| EP (2) | EP4245295B1 (es) |
| JP (1) | JP7179755B2 (es) |
| KR (1) | KR102658724B1 (es) |
| CN (1) | CN110650740A (es) |
| AU (2) | AU2018248425B2 (es) |
| BR (1) | BR112019020430A2 (es) |
| CA (1) | CA3058654A1 (es) |
| CL (1) | CL2019002839A1 (es) |
| CO (1) | CO2019012336A2 (es) |
| EA (1) | EA201992356A1 (es) |
| ES (2) | ES3046717T3 (es) |
| IL (1) | IL269743B (es) |
| MX (1) | MX394915B (es) |
| MY (1) | MY199462A (es) |
| NZ (1) | NZ757769A (es) |
| SG (1) | SG11201909207VA (es) |
| TW (1) | TW201841636A (es) |
| UA (1) | UA125658C2 (es) |
| WO (1) | WO2018187473A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110636844A (zh) * | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
| KR20210065950A (ko) * | 2018-09-26 | 2021-06-04 | 알카헤스트 인코포레이티드 | Ccr3-억제제를 사용한 노화 관련 장애 치료를 위한 방법 및 조성물 |
| US20230312697A1 (en) * | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
| CN112322719A (zh) * | 2020-11-06 | 2021-02-05 | 温州医科大学 | 循环血外泌体miRNA作为视网膜静脉阻塞疾病诊断标志物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2002112800A (ru) | 2002-05-16 | 2004-03-10 | Евгений Ильич Зарайский (RU) | Способ лечения диабетической ретинопатии |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| EP2785338A1 (en) | 2011-12-01 | 2014-10-08 | Glaxo Group Limited | Methods of treatment and prevention of eye diseases |
| US8680280B2 (en) | 2012-04-02 | 2014-03-25 | Boehringer Ingelheim International Gmbh | Process for the manufacturing of CRR inhibitors |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| CN110636844A (zh) | 2017-04-05 | 2019-12-31 | 万能溶剂有限公司 | 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物 |
-
2018
- 2018-04-04 MY MYPI2019005833A patent/MY199462A/en unknown
- 2018-04-04 AU AU2018248425A patent/AU2018248425B2/en active Active
- 2018-04-04 ES ES23168381T patent/ES3046717T3/es active Active
- 2018-04-04 BR BR112019020430-0A patent/BR112019020430A2/pt not_active IP Right Cessation
- 2018-04-04 EP EP23168381.4A patent/EP4245295B1/en active Active
- 2018-04-04 MX MX2019012012A patent/MX394915B/es unknown
- 2018-04-04 IL IL269743A patent/IL269743B/en unknown
- 2018-04-04 NZ NZ757769A patent/NZ757769A/en unknown
- 2018-04-04 ES ES18720836T patent/ES2950453T3/es active Active
- 2018-04-04 US US16/603,084 patent/US11590118B2/en active Active
- 2018-04-04 CN CN201880023759.8A patent/CN110650740A/zh active Pending
- 2018-04-04 SG SG11201909207V patent/SG11201909207VA/en unknown
- 2018-04-04 UA UAA201910857A patent/UA125658C2/uk unknown
- 2018-04-04 KR KR1020197032819A patent/KR102658724B1/ko active Active
- 2018-04-04 EA EA201992356A patent/EA201992356A1/ru unknown
- 2018-04-04 EP EP18720836.8A patent/EP3606521B1/en active Active
- 2018-04-04 JP JP2019554738A patent/JP7179755B2/ja active Active
- 2018-04-04 WO PCT/US2018/026091 patent/WO2018187473A1/en not_active Ceased
- 2018-04-04 CA CA3058654A patent/CA3058654A1/en active Pending
- 2018-04-09 TW TW107112125A patent/TW201841636A/zh unknown
-
2019
- 2019-10-04 CL CL2019002839A patent/CL2019002839A1/es unknown
- 2019-11-01 CO CONC2019/0012336A patent/CO2019012336A2/es unknown
-
2023
- 2023-02-16 US US18/170,384 patent/US11951102B2/en active Active
-
2024
- 2024-06-18 AU AU2024204133A patent/AU2024204133B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012336A2 (es) | Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3 | |
| ZA202102488B (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| HK1258588A1 (zh) | 用於治疗眼科疾病的化合物和制剂 | |
| MX2021006092A (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
| MX2017016655A (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| BR112018012876A2 (pt) | bisturi oftálmico e métodos de uso | |
| MX2016010777A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer. | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| CO2017004530A2 (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 | |
| MX2017002374A (es) | Composiciones y metodos para tratar trastornos de la vision. | |
| EA201891727A1 (ru) | Композиции на основе дейтерированного домперидона и способы терапии расстройств | |
| MX385405B (es) | Composición inyectable en el vítreo de un ojo que comprende un inhibidor de cinasa y el uso de la misma para tratar una enfermedad ocular. | |
| MX385698B (es) | Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares | |
| NZ712030A (en) | Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists | |
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| EA201990752A1 (ru) | Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы | |
| IL274233A (en) | Compounds, preparations and methods for the treatment of eye disorders and skin diseases | |
| CO2018003596A2 (es) | Arnip y su uso en métodos y composiciones para la inhibición de la expresión del gen nrarp | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
| HK1219654A1 (zh) | 用於治疗眼科疾病和病症的方法 | |
| BR112017007102A2 (pt) | uso de um medicamento no tratamento de patologias da córnea, composição oftálmica para uso de um medicamento no tratamento de doenças da córnea e método para preparar a composição oftálmica | |
| HK40058483A (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| AR103055A1 (es) | Tratamiento de la degeneración de la retina mediante el uso de células progenitoras | |
| UA107275U (uk) | Спосіб візуалізації судин та макулярної зони сітківки ока при цукровому діабеті |